{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:45:36Z","timestamp":1790725536234,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.intimp.2019.02.037","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:26:46Z","timestamp":1552436806000},"page":"40-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases"],"prefix":"10.1016","volume":"71","author":[{"given":"Hamidreza","family":"Mahmoudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Balighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.02.037_bb0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","article-title":"Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review","volume":"54","author":"Tavakolpour","year":"2017","journal-title":"Int. Immunopharmacol."},{"issue":"10083","key":"10.1016\/j.intimp.2019.02.037_bb0010","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.intimp.2019.02.037_bb0015","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.intimp.2019.02.037_bb0020","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jocn.2015.08.033","article-title":"Rapid exacerbation of neuromyelitis optica after rituximab treatment","volume":"26","author":"Dai","year":"2016","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"issue":"11","key":"10.1016\/j.intimp.2019.02.037_bb0025","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ibd.20215","article-title":"Exacerbation of ulcerative colitis after rituximab salvage therapy","volume":"13","author":"Goetz","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.intimp.2019.02.037_bb0030","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ajd.12002","article-title":"Exacerbation of lymphomatoid papulosis during rituximab therapy","volume":"55","author":"McCurdy","year":"2014","journal-title":"The Australasian Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2019.02.037_bb0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jdcr.2015.11.006","article-title":"Exacerbation of bullous pemphigoid after hand, foot, and mouth disease treated with rituximab","volume":"2","author":"Batts","year":"2016","journal-title":"JAAD Case Reports"},{"issue":"3","key":"10.1016\/j.intimp.2019.02.037_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2012.08.010","article-title":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients","volume":"68","author":"Leshem","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2019.02.037_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0378-6323.174379","article-title":"Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study","volume":"82","author":"Sharma","year":"2016","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"3","key":"10.1016\/j.intimp.2019.02.037_bb0050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/bjd.13823","article-title":"Paradoxical worsening of pemphigus vulgaris following rituximab therapy","volume":"173","author":"Feldman","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2019.02.037_bb0055","first-page":"e05","article-title":"Exacerbation of pemphigus foliaceus in a child after rituximab treatment, Transl","volume":"2","author":"M","year":"2016","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.intimp.2019.02.037_bb0060","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000448031","article-title":"Assessment of the effects of rituximab monotherapy on different subsets of circulating T-regulatory cells and clinical disease severity in severe pemphigus vulgaris","volume":"232","author":"Bhattacharjee","year":"2016","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"6","key":"10.1016\/j.intimp.2019.02.037_bb0065","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2019.02.037_bb0070","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2019.02.037_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000485","article-title":"Effect of Fc\u03b3-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis","volume":"3","author":"P\u00e1l","year":"2017","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.intimp.2019.02.037_bb0080","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","article-title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma","volume":"15","author":"Terui","year":"2009","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.intimp.2019.02.037_bb0085","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient","volume":"130","author":"Lunardon","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2019.02.037_bb0090","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2009-06-229112","article-title":"Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance","volume":"115","author":"Henry","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2019.02.037_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/exd.12299","article-title":"Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus","volume":"23","author":"Gamonet","year":"2014","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2019.02.037_bb0100","first-page":"45","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis"},{"issue":"5","key":"10.1016\/j.intimp.2019.02.037_bb0105","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jaad.2008.01.007","article-title":"Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus","volume":"58","author":"Czernik","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"17","key":"10.1016\/j.intimp.2019.02.037_bb0110","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N. Engl. J. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919301353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919301353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:12:03Z","timestamp":1761585123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919301353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":22,"alternative-id":["S1567576919301353"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.02.037","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.02.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}